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Omic  techniques  have  become  key  tools  in  the development  of  systems  biology.  As  the  holistic  approaches
underlying  the  practice  of traditional  Chinese  medicine  (TCM)  and  new  tendencies  in Western  medicine
towards  personalised  medicine  require  in-depth  knowledge  of mechanisms  of  action  and  active  com-
pounds,  the  use of omic  techniques  is  crucial  for understanding  and  interpretation  of  TCM  development,
especially  in  view  of  its expansion  in  Western  countries.  In this  short  review,  omic  applications  in  TCM
research  are  reviewed  which  has  allowed  some  speculation  regarding  future  perspectives  for  theseenomics
ranscriptomics
etabolomics
etabonomics
roteomics
raditional Chinese medicine
hinese herbal medicine
approaches  in  TCM  modernisation  and  standardisation.  Guidelines  for  good  practice  for the application
of  omics  in  TCM  research  are  also proposed.
© 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.. IntroductionIdentiﬁcation of molecular mechanisms and targets is a crit-
cal step in the validation of a biological effect. When using
 The literature contains many abbreviated forms to describe the techniques often
ollectively known as the omic techniques. We prefer the use of the simple brief term
mics; without complicating punctuation.
 For clarity throughout this article, Latinised pharmacopoeial names are shown
n  bold italics to differentiate them from Latin binomial plant names which are ital-
cised only. The Pinyin versions of Chinese and Japanese formula names are shown
n bold.
∗ Corresponding author. Tel.: +44 207 848 4387; fax: +44 207 848 4217.
E-mail address: peter.2.hylands@kcl.ac.uk (P.J. Hylands).
1 Both authors contributed equally as major contributors to this article.
378-8741 © 2012 Elsevier Ireland Ltd. 
oi:10.1016/j.jep.2012.01.055
Open access under CC BY-NC-ND license.phytocomplexes2 as in Chinese herbal medicine (CHM) research,
this is often hampered by the complexity of the molecular mix-
tures, with many different molecules participating to the overall
effect, either positively or negatively.
With the advent of information-rich techniques such as
genomics, proteomics and transcriptomics as well as various proﬁl-
ing approaches, including metabolomics (a non-targeted analytical
approach, usually concentrating on molecules of low molecu-
lar weight) and metabonomics (similar studies but involving
studying the effects of perturbation of a system [see precise
deﬁnitions in Section 3.3]), it has recently become possible to
examine simultaneous molecular effects of mixtures of chemical
2 The term “phytocomplexes” is taken here to mean the use of a whole plant or
part, or its extract (thus containing many components) or indeed mixtures of such
plant parts or extracts, as in common in TCM.
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of the total number of articles published.
Pharmaco-toxicological studies of CHM using omic techniques
addressing biological effects and pathway perturbation began in36 A. Buriani et al. / Journal of Ethn
gents (Ulrich-Merzenich et al., 2007) and, with the help of bio-
nformatics, to look at such effects with a global view on the
iological system affected. Factorial analytical models can decode
he large quantity of raw information derived from these omic
echniques, sometimes allowing correlation of the multiple compo-
ents of phytocomplexes with their biological effects (Wang et al.,
010a,b).
At the same time high-throughput, information-rich assays can
e used to ﬁngerprint herbs and botanical extracts (Heubl, 2010;
im et al., 2011; Liang et al., 2010; Sucher and Carles, 2008; Van
er Kooy et al., 2009). A number of studies have thus begun to
ddress the other key issue of quality control and sample vari-
bility, which is pivotal for reproducibility and standardisation
f biological effects in the study of herbal preparations. Many
apers, particularly those reporting clinical data, do not adequately
ddress the quality (or even the identity) of the test material, so
igniﬁcantly reducing the validity of the results. Although some
nternational journals are beginning to require authors to give
etails of their test materials, not all yet do so and one of the rec-
mmendations of the present group relates to such a proposal (see
ection 6.2).
Such applications of information-rich approaches make the
se of omic techniques particularly appropriate for addressing
any of the problems encountered in traditional Chinese medicine
TCM) research that have hampered its acceptance in the West-
rn biomedical mainstream and its integration with more orthodox
estern medical practice.
Today, a holistic systems biology approach provides a new per-
pective in pharmacological sciences which goes beyond target
peciﬁcity and single molecule pharmacology, and embraces the
ntire equilibrium of a biological system undergoing simultane-
us perturbations on primary and secondary multiple molecular
argets (Auffray et al., 2009). This approach is even more rel-
vant when using multichemical mixtures, as in CHM and
ther TCM formulae which comprise mixtures of mixtures
Cooper, 2009; Ulrich-Merzenich et al., 2009; Wang et al.,
009).
The advent of such assays with advanced bioinformatics has
hus brought an opportunity to change the way the different experi-
ental levels are considered, long viewed almost as different ﬁelds.
he operation of the different omic techniques are applied in an
dentical fashion whether used in vitro, in vivo or in clinical research.
ith the new systems biology approach the difference is only seen
n terms of its application to increasing system complexity: molec-
lar, cellular, multicellular, organ and whole organism levels. Thus,
hen reviewing omic techniques in experimental models, it is
mportant to include in vitro, in vivo and clinical research applica-
ions. Omic techniques are of equally useful application in all such
ontexts, and researchers from different levels should be able to
eadily share and transfer information within the research com-
unity and to the clinic.
These approaches obviously have great potential, as shown by
ecent applications of omic techniques in TCM research, which are
he focus of the present review. It is to be emphasised that the
erm ‘holistic’ is often used to describe the application of omic tech-
ologies (being non-reductive in that they do not focus on single
ctive principles), the information derived from them is obviously
t the level of physical matter (albeit by considering many com-
ounds and their effects at once). This is attractive in the context
f research on Chinese herbal medicine which is described as hav-
ng a holistic, multidimensional approach to treating patients but
he use of the term must be carefully differentiated according to
ontext. The authors nonetheless contend that the use of non-
eductive technologies is highly appropriate to begin to understand
he complexities of the use of herbal materials at the molecular
evel.macology 140 (2012) 535– 544
2. Development of the use of omic techniques in TCM
research
Since their origin at about the beginning of this century, omic
techniques have found application in virtually all biomedical ﬁelds
and have rapidly found complementarity with many classical
experimental models. Systems biology and, on the clinical research
side, personalised medicine, have given rise to an emerging holistic
approach in research, which zooms out the focus from the static
detail of single molecular targets to try to embrace the biologi-
cal system in its dynamic complexity. Omic techniques, allowing
a simultaneous vision of classes of molecules in a given system, are
the main experimental drivers of such an approach. Accordingly,
information-rich assays can be applied to the ﬁne description of a
complex formulation, a multi-target biological context as well as
to the observation of their interactions and the subsequent pertur-
bation of the biological equilibrium. Despite the apparent potential
for application of omic analytical techniques and bioinformatics in
studies involving herbal medicine, high cost and the range of mul-
tidisciplinary expertise required for their application have initially
constrained the speed of their acceptance and dissemination to a
pace slower than might have been expected.
From a PubMed search restricted to subjects of pharmaco-
toxicological interest, using as keywords (contained in the titles
or abstracts) the commonly used omic techniques together with
herbal studies3; it has been found that in the last ten years or so;
some 3300 papers have been published on omic techniques applied
in the study of medicinal plants. More than one third of them have
appeared in the last four years. However; as there are only about
130 titles having a clear mention of the area of Chinese medicine
in their titles or abstracts; omics applied to TCM research still rep-
resents only a small fraction of the total of omic work published;
even though this proportion is increasing.
Interestingly, when looking into the individual omic techniques
and their applications, it is clear that a linear path cannot be traced
in the evolution of omics techniques in CHM. The application of
newer generation omic strategies, such as metabonomics, is rapidly
catching up those from the ﬁrst generation of omics that were
based mostly upon genomic and transcriptomic techniques. This
is illustrated in Fig. 1.
During the early years of their application in CHM research,
omic techniques were used almost exclusively as tools for botan-
ical identiﬁcation purposes, using genomic techniques like DNA
sequencing and ﬁngerprinting, or DNA microarrays (Cai et al., 1999;
Mihalov et al., 2000; Zhang et al., 2003). Until 2007, about 50%
of original papers on omics and TCM related to botanical issues,
mostly addressing authentication and quality control of Chinese
herbal medicinal products (Zhao et al., 2006). During this period, in
addition to DNA-based tools, other omic analytical techniques had
been introduced to the ﬁeld of herbal identiﬁcation, for example,
metabolomic proﬁling has been used for herbal authentication and
ﬁngerprinting (Murch et al., 2004). This methodology has recently
gained momentum (Frédérich et al., 2011; Kang et al., 2008; Xie
et al., 2008; Xiang et al., 2011), together with the improvement
of DNA ﬁngerprinting performed with novel techniques, like DNA
barcoding (Ma  et al., 2010a; Zuo et al., 2011).
Since 2008, in parallel with the increase in pharmacological
studies, a steady trend has been established for papers on omics
applied to botanical studies of TCM, and now represents one quarter3 The complete string for the Boolean search on PubMed performed on 1 October
2011 is shown in the supporting information.
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eig. 1. Histogram showing the total number of pharmaco-toxicological publications
edicine) 2000–2011 (up to September only for 2011) from a bibliographic search 
he early 2000s (Lee et al., 2002), following mainstream scientiﬁc
volution of their application to pharmacological studies (Zanders,
000). Since then there has been a limited, but signiﬁcant, pro-
uction of experimental work in the ﬁeld using both reductionist
s well as holistic approaches. In the last two years about twenty
apers per year were published, very few considering that they rep-
esented slightly more than 5% of all papers dealing with omics and
erbal preparations in this period. Nevertheless, this small number
epresented a jump from a production of only few articles per year
efore 2008, thus setting a positive trend.
From the beginning, most activity-oriented papers have used
mic techniques with a holistic approach, with experimental mod-
ls appropriate for the examination of multi-chemical perturbation
f multiple targets. Indeed this represents the real context in which
HM should be characterised pharmacologically (Kang, 2008),
hus exploiting the full potential of the systems biology approach
Auffray et al., 2009; Naylor and Chen, 2010). Taken together, sys-
ems biology and omic techniques represent a unique opportunity
o understand the complex biological perturbations as the expla-
ation of and the basis for the application of TCM for therapeutic
ntervention and disease prevention. TCM offers a large number
f examples in which several active ingredients in one prescrip-
ion are aimed at numerous targets and work together to provide
herapeutic beneﬁts, a concept that has been given the deﬁnition
f “magic shrapnel”, or “herbal shotgun” as opposed to the “magic
ullet”, or “silver bullet”, concept (Chen et al., 2006; Williamson,
001), which for many years has driven the quest for pharmacolog-
cally active molecules. Phytopharmaceutical research has indeed
ocused for long on the search for the (mostly single) “active prin-
iple”, but single components can behave in completely different
ays from a phytocomplex. A change of paradigm towards the
pplication of complex mixtures in medicine may  thus be pos-
ible with the application of omic technologies, paving the way
o new ﬁelds of phytogenomics, -proteomics and -metabolomics
Ulrich-Merzenich et al., 2007).
The present Boolean search indicates that, as with botanical
haracterisation studies, experimental pharmacological models in
HM have followed the mainstream evolution of omics techniques
Fig. 2). Thus, initially DNA microarrays for transcriptomic analy-
is were the tools most frequently used, then the use of proteomic
trategies became more frequent in the mid-2000s, while wider
pplication of metabonomic approaches emerged later, and are
ow looked at with increasing interest in the TCM research com-
unity.
Thanks to their unique ability to simultaneously monitor the
xpression of thousand of genes, cDNA and/or oligonucleotide broad ﬁeld of the application of omics to medicinal herbs (not restricted to Chinese
d out in October 2011.
microarrays have been used in vitro and in vivo to identify pathways
affected by phytocomplexes from CHM, both from single medicinal
plants and from Chinese formulae. Such a transcriptomic approach
has been used to study the biological effect of CHM in a wide range
of conditions, from cancer to ﬁbrosis, and gastrointestinal, neu-
rological, metabolical and immune disorders (Cheng et al., 2008;
Efferth et al., 2011; Guo et al., 2010; Kang et al., 2005; Meng et al.,
2010; Pan-Hammarström et al., 2006; Sakai et al., 2007; Sun et al.,
2008; Watanabe-Fukuda et al., 2009; Wang et al., 2011a,b,c; Yin
et al., 2004; Zhuang et al., 2004). An interesting recent develop-
ment in the use of transcriptomics indicated that this method can be
used as a platform for translational research in CHM, by comparing
the transcriptomic patterns with genetic databases of drug-altered
genes (Lamb, 2007), drug metabolism-related genes and toxicity-
associated genes (Hayes et al., 2005). Indeed these combinations
might allow improved therapeutic prediction, drug development
and safety evaluation (Cheng et al., 2010; Wen  et al., 2011).
Proteomic techniques have been applied to CHM treatment
in, for example, cardiovascular disease, epilepsy, cancer and psy-
chiatric conditions (Fan et al., 2010; Hung et al., 2010; Lo et al.,
2010; Pennington et al., 2009; Tian et al., 2010). In almost all cases
proteomic analysis was performed in in vitro experimental mod-
els using two-dimensional gel electrophoresis coupled with mass
spectrometric peptide analysis, but the affected pathways were not
always thoroughly characterised.
In contrast to proteomics, metabonomic studies have been per-
formed in in vivo models or involving human samples, in most cases
using urine. Metabolic proﬁles are most frequently obtained using
ultra-performance liquid chromatography coupled with mass spec-
trometry (UPLC/MS) and followed by multivariate analysis. The
use of metabonomics is only relatively recent in the TCM research
ﬁeld, and only a few articles have been published so far, but there
seems to be a rapidly increasing consensus among researchers
that metabonomics might actually develop into the most feasible
omic technique for CHM studies, not only for its ability to gen-
erate a complete perspective of the functional consequences of
ectogenic stimuli, but also for the noninvasive, simple and less
expensive characteristics of the methods (Wang et al., 2010a,b).
Indeed metabonomics is based on the analysis of entire patterns
of low molecular weight compounds, rather than focusing on indi-
vidual metabolites whether of high or low molecular weight, thus
allowing a vision on complete organism pathways following expo-
sure to a perturbation (Lu et al., 2011; Su et al., 2011). This strategy
coincides well with the integrative and systemic features of TCM,
and has been chosen by several to study Chinese medicine syn-
drome patterns (Lu et al., 2011; Mamtimin et al., 2011; Wang et al.,
538 A. Buriani et al. / Journal of Ethnopharmacology 140 (2012) 535– 544
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ut  in October 2011. The ﬁrst main application of all techniques was in plant deﬁni
ave  increased.
010a,b) involving cancer, psychiatric conditions, cardiovascular
isease, and gastric and renal diseases and dysfunctions (Liang et al.,
010; Ma  et al., 2010b; Mamtimin et al., 2011; Su et al., 2011).
otably, most authors extol the advantages of using metabonomic
pproaches.
The examples given in this paper cannot be exhaustive and are
imply meant to be representative of the literature (emphasizing
he sectors in which work has been done and to indicate the likely
irection of development in the application of the techniques men-
ioned).
. Omic techniques most frequently used in TCM research
.1. Genomics
Quality control and sample variability of TCM materials and
roducts are among the ﬁrst issues successfully addressed by
mics techniques in the TCM research ﬁeld. A number of DNA
olymorphism-based assays have been developed for the identi-
cation of herbal products, where DNA is ampliﬁed by polymerase
hain reaction (PCR) and the cDNA can be sequenced, a procedure
tilised in TCM research to identify different species of Fritillaria as
arly as 1999 (Cai et al., 1999). DNA chips with DNA sequences
nique to a given species of medicinal plant were soon devel-
ped for plant material identiﬁcation and applied to CHM samples
Carles et al., 2001). This proved to be a more powerful tool that
an also be used for analyzing mixed herbal preparations, which
or instance, allowed the determination of Dendrobium nobile in
 Chinese medicine formulation containing nine different herbal
omponents (Zhang et al., 2003). Thus DNA chip technology can
rovide a rapid, high-throughput and information-rich tool for
enotyping, quality assurance and species authentication (Chavan
t al., 2006; Tsoi et al., 2003).
A further development of DNA chip technology is represented
y the “DNA barcoding” method, which can be used for recog-
ition and identiﬁcation of plant samples through comparison of
equences of a standard short DNA fragment, “DNA barcode”, from
n unknown specimen to a library of reference sequences from
nown species. An optimal DNA barcode region is a small frag-
ent present in all species of a major taxonomic group, having
nvariable nucleotide sequence in all members of the same species,
ut with sufﬁcient variation to discriminate species (Hollingsworth
t al., 2011). This method has been used for establishing an accu-
ate and effective identiﬁcation system for Panax species. Using
5 ginseng samples, representing all the species in the genus,ears 1999–2011 (up to September only for 2011) from a bibliographic search carried
ut in the last few years transcriptomic, proteomic and metabonomics publications
considerable differences were found in the performance of the
potential barcoding regions and an efﬁcient method for identifying
all the species and clusters in the genus was established (Zuo et al.,
2011). This is a more powerful methodology compared to the pre-
vious techniques used for identifying ginseng samples, such as DNA
ﬁngerprinting by rapid ampliﬁcation of polymorphic DNA (Mihalov
et al., 2000), microchip electrophoresis coupled with the PCR-short
tandem repeats (STR) technique, and ﬂuorescence detection (Qin
et al., 2005).
New innovative automated assays and speciﬁc tools for DNA
analysis are continuously emerging, including mini sequenc-
ing, nanoscale DNA sequencing or microsphere-based suspension
arrays which have a high multiplexing capacity and great potential
for genotyping and future taxon identiﬁcation. These will undoubt-
edly contribute to the next generation of genomic technologies
(Heubl, 2010).
DNA-based techniques thus represent an effective platform for
CHM identiﬁcation. Nevertheless, they have certain limitations,
mostly related to the quality and quantity of the DNA from dried
or processed materials, as well as high concentrations of secondary
plant metabolites which may  inﬂuence DNA extraction or PCR reac-
tion. In addition, different parts of the same plant and herbs of the
same species grown under different conditions have the same DNA
sequences but their quality, clinical utility and indications might
be very different.
Microarray analysis of gene expression is a mature gene chip
technology that allows rapid and detailed analysis of thousands of
transcripts. When used in this way, the microarray and other rele-
vant methods are referred to as transcriptomic technologies. Given
their ability to identify simultaneously the variations in expression
of multiple genes, this represents one of the most powerful tools for
elucidating the molecular mechanisms and networks underlying
the complex pharmacological function of CHM preparations and,
properly coupled with bioinformatics and statistical tools, it can be
applied to pharmacodynamic, pharmacokinetic and toxicological
characterisation of herbal drugs. A positive correlation between the
herbal drug induced transcriptional pattern and a transcriptomic
database proﬁle of a known therapeutic agent, by comparison, can
suggest target speciﬁcity, mechanism of action and downstream
effects. Likewise it is possible to gain insight into toxicological
effects by comparing gene expression proﬁles with those known to
be relevant to toxicity, or for drug metabolism (Chavan et al., 2006).
In addition, several molecular mechanisms and targeted pathways
have been elucidated in CHM using transcriptomics. Some exam-
ples of in vitro and in vivo transcriptomic studies of CHM are given
below.
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IA. Buriani et al. / Journal of Ethn
cDNA microarrays have been used to investigate the mech-
nism of action of Tripterygium hypoglaucum-induced apoptosis
n HL-60 cells. Sixteen genes were identiﬁed to be differentially
xpressed upon treatment, including NF-B-related genes, c-myc
inding protein, caspase-3 and caspase-8. This allowed insight
nto the mechanisms of its pro-apoptotic activity (Zhuang et al.,
004). Cell growth arrest and apoptosis were also the subject of
 study investigating the in vitro effect of an extract of Coptidis
hizoma (the rhizome of Coptis chinensis) on human breast can-
er cells. In this case the use of DNA microarray revealed that
FN- mRNA was dramatically upregulated, suggesting that the
ntiproliferative effect might be mediated by interferon- (Kang
t al., 2005). The induction of cytokines was also investigated in
oth peripheral blood mononuclear cells and spleen cells upon
reatment with VI-28,  a TCM formula comprising principally
adix Ginseng, Cornu Cervi Pantotrichum and Fructus Cnidii,
o investigate its effect on immune function. The cytokine gene
xpression proﬁle showed several cytokine and cytokine-related
enes to be differentially regulated, suggesting an effect on both
nnate and acquired immune functions (Pan-Hammarström et al.,
006).
The effect of San Huang Xie Xin Tang, a TCM formula tra-
itionally comprising a mixture of roots of Scutellaria baicalensis
nd Coptis chinensis with the root and rhizome of rhubarb species
Rheum sp.), on a human hepatoma cell line (HepG2 cells), was
nvestigated in vitro using DNA microarrays. Gene set enrichment
nalysis indicated that the cytotoxic effect of the phytocom-
lex was in some way associated with changes in the p53
ignalling pathway. Using a network analysis to visualise the
ossible relationship between p53 and other regulated genes, it
as established that most of them were connected to p53, thus
ndicating a central role for p53 in the apoptosis-inducing net-
ork. Moreover, using hierarchical cluster analysis, it was  shown
hat one of the plants in the formula, Rhizoma Coptis,  showed
 similar pattern, thus allowing the identiﬁcation of the likely
rincipal component of the formula for this effect (Cheng et al.,
008).
DNA microarrays used in vivo were usually associated with the
haracterisation of the pharmacological effect of TCM. In an exper-
mental mouse model of Parkinson’s disease, microarray analysis
as performed using Genechip® Mouse Genome Array, follow-
ng treatment with Tokito,  a TCM-derived Japanese herbal remedy
omprising ten medicinal plants (Angelicae Radix,  Pinelliae Tuber,
innamoni Cortex,  Ginseng Radix,  Magnoliae Cortex,  Paeoniae
adix, Astragali Radix,  Zanthoxyli Fructus, Zingiberis Siccatum
hizoma and Glycyrrhizae Radix),  that had been previously shown
o alleviate symptoms in some patients with Parkinson’s disease.
he analysis allowed the identiﬁcation of a down-regulated gene,
he serum and glucocorticoid regulated kinase (SGK), believed to be
nvolved in the pathogenesis of Parkinson’s disease, thus suggest-
ng a molecular mechanism for the effect of Tokito (Sakai et al.,
007).
Orengedokuto, another TCM-derived Japanese herbal medicine
usually comprising Coptidis Rhizoma, Scutellariae Radix,
hellodendri Cortex and Gardeniae Fructus), used for various
ndications including gastric ulcers and gastritis, protects mice
rom indomethacin-induced enteropathy. This effect was studied
n vivo using a transcriptomic approach to guide the search for
he molecular mechanism(s). Gene expression data indicated
hat the adenosine system, especially adenosine deaminase,
ight be involved in the effect–this result was  then validated
y biological experiments (Watanabe-Fukuda et al., 2009). As
eviewed in this special issue by Liu and Cheng (2012),  PHY906
s a standardised TCM formula under clinical evaluation as an
djuvant to relieve the side effects associated with chemotherapy.
t comprises a formulation of four Chinese herbs: Glycyrrhizamacology 140 (2012) 535– 544 539
uralensis, Paeonia lactiﬂora, Scutelleria baicalensis and Ziziphus
jujube. Using a murine tumour model, gene expression was
studied in groups of animals treated by an antitumour com-
pound (CPT-11), PHY906 or their combination. Gene expression
microarray analysis was  performed using RNA from tumour
tissues or control tissues. The results indicated that the networks
activated by CPT-11 and PHY906 were different, though both
acted on pathways relevant to the antitumour effect. Impor-
tantly, when used in combination, the gene expression pattern
changed and the antitumour effect of CPT-11 was enhanced,
with prevalent induction of pro-apoptotic and pro-inﬂammatory
pathways that may  favour tumour elimination (Wang et al.,
2011a,b,c).
The full transcriptomic potential though can be more appreci-
ated when using genetic association databases. By comparing the
gene expression signatures of formulae with those of disease states
or known drugs, it is possible to predict unknown biological effects
or either identify or exclude unwanted interactions with drugs or
toxicological effects (Youns et al., 2010). One such example was
carried out by Cheng et al. (2010).
Transcriptomics was  actually used as a platform of translational
medicine, and DNA microarray technology was used to analyse the
biological events induced in mice by 15 different herbal formulae
to predict their therapeutic potential, as well as their safety. The
assays were performed using Mouse Whole Genome OneArrayTM;
groups of up-regulated genes were detected and 352 pathways
were analysed using several on-line databases. Then a connec-
tion analysis of formulae-altered genes and diseases-altered genes
was performed using the genetic association database (Becker
et al., 2004). The expression signatures of formulae-regulated
genes were connected with those of drug-regulated genes using
the Connectivity Map  (Lamb, 2007). Analysis of expression lev-
els of genes associated with drug metabolism and toxicity was
also performed. Using this strategy it was possible to establish sig-
niﬁcant similarities with expression signatures and a surprisingly
high number of ﬁndings was achieved, allowing the prediction
of both therapeutic potential and safety of the formulae ana-
lysed (Cheng et al., 2010). A systematic approach using DNA
microarrays, bioinformatics and the Connectivity Map was  also
used in vitro to examine TCM-induced changes in gene expres-
sion.
The herbal formula Si Wu  Tang, comprising Radix Angeli-
cae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Alba and
Radix Rehmanniae Preparata,  traditionally used in oestrogen-
related disorders, was added to MCF-7 human breast cancer cells.
Signiﬁcant gene expression changes were observed and the Si
WuTang-induced gene expression proﬁle was compared with
those of 1309 compounds in the Connectivity Map  database. Con-
sistent with the formula’s claimed use for women’s health, the
Connectivity Map  of estradiol-treated MCF-7 cells showed an
excellent match with Si Wu  Tang treatment, suggesting a phytoe-
strogenic effect (Wen  et al., 2011).
Transcriptomic information can be adapted into microRNomics,
a technical approach devoted to expression of miRNAs – the expres-
sion of approximately one third of the transcripts is controlled by
miRNAs, small non-coding RNAs that regulate gene expression and
emerge as critical mediators of diseases (for review, see Bartel,
2009). miRNA studies are likely to be important in TCM research
although existing data are scarce and most of those that have
been reported concern cases where TCM compounds were used
as chemotherapy co-adjuvants. For example, it was reported that a
TCM product, Aidi injection (prepared from cantharidin, together
with species of the genera Panax,  Astragalus and Acanthopanax)
changed breast-cancer miRNA proﬁling which might suggest that
miRNA alterations could be one of the mechanisms of action in TCM
(Zhang et al., 2011).
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.2. Proteomics
Proteomics emerges as an area that promises to transform
iology and medicine, since changes in mRNA expression often
orrelate poorly with changes in protein expression, and protein
unction depends on many post-translational modiﬁcation and
aries with protein localisation. Thus proteomic research aims at
nderstanding the expression and functions of proteins on a global
evel and requires to be integrated with other information such as
roﬁles of genes, mRNAs and metabolites, in order to fully under-
tand how biological systems work. The integrative proteomic
pproach thus exactly maps to the holistic concept and practice
f TCM. Proteomic technologies have been used to study phar-
acological effects and mechanisms of action of relevant CHM, to
dentify target molecules for CHM or even to identify new bioactive
omponents.
Currently, two approaches based on mass-spectrometry are the
ost frequently used for global quantitative protein proﬁling: (1)
wo-dimensional electrophoresis (2DE) followed by staining, selec-
ion and identiﬁcation by mass-spectrometry; (2) isotope tags to
abel proteins, separation by multidimensional liquid chromatog-
aphy and mass spectrometry analysis (for review, see Kandal et al.,
009; Weston and Hood, 2004). Both basic proteomic approaches
an be supplemented with useful information provided by molec-
lar imaging. In fact, combination of proteomic approaches and
n vivo imaging has been successfully used for the study of the
etabolism of ﬂavonoids from Herba Epimedii in zebra ﬁsh (Li
t al., 2011).
One of the most interesting applications of proteomics in CHM is
he ability of these techniques to identify different species as in the
ase of Panax (P. ginseng vs. P. quinquefolium)  (Lum et al., 2002). This
ill be a very valuable tool for quality control, toxicity studies and
tandardisation of TCM preparations and decoctions, key points in
he use of CHM in Western countries.
Complementary to genomic and transcriptomic approaches,
roteomic assays have been successfully used for describing mech-
nisms of action of many different TCM preparations, such as Si
u Tang decoction effects in general health (Guo et al., 2004),
anoderma properties in nerve injury (Zhang et al., 2006), Salvia
iltiorrhiza effects on atherosclerotic lesions (Hung et al., 2010)
s well as several other effects of preparations in cancer, which
ave been investigated at the proteomic level (Hung et al., 2010).
n addition, the use of proteomic data has also shed light into the
ffect of the TCM formula Shuanglong on differentiation and use of
luripotential cells in myocardial ischemia repair (Fan et al., 2010).
Although interpretation of proteomics as well as other omic
echniques is difﬁcult due to their inherent complexity, com-
ounded in view of the variety of the components in TCM
ecoctions, proteomics is nonetheless becoming a useful tool
or elucidating multitarget effects of complex herbal prepara-
ions, as well as for the discovery of single bioactive compounds,
evelopment of active fractions, characterisation of safe herbal pre-
criptions and eventually personalised molecular diagnosis for TCM
reatments (Cho, 2007).
.3. Metabolomics and metabonomics
“Metabonomics broadly aims to measure the global, dynamic
etabolic response of living systems to biological stimuli or genetic
anipulation. The focus is on understanding systemic change
hrough time in complex multi cellular systems. Metabolomics
eeks an analytical description of complex biological samples, and
ims to characterise and quantify all the small molecules in such a
ample. In practice, the terms are often used interchangeably, and
he analytical and modelling procedures are the same” (Nicholson
nd Lindon, 2008).macology 140 (2012) 535– 544
Metabonomics in pharmaceutical research and develop-
ment has been reviewed (Lindon et al., 2006). The term
metabolomics was actually coined for comprehensive, nonbiased,
high-throughput analyses of complex metabolite mixtures typi-
cal of plant extracts (Hall et al., 2002), and the use of this term
is mostly restricted to this ﬁeld. Chromatographic ﬁngerprinting
of CHM has proved to be a comprehensive strategy for assess-
ing quality of herbal medicines (Liang et al., 2010). Metabolomic
proﬁling using Fourier transform ion cyclotron mass spectrom-
etry (FTMS) has been used for screening extracts from different
germplasm lines of Scutellaria baicalensis to proﬁle, identify and
quantitatively compare metabolites, with the aim of identifying the
best phytochemical proﬁles and to compare the effects of different
growth conditions (Murch et al., 2004). NMR  spectroscopy-based
metabolomics has been used to differentiate Panax ginseng roots
of different origins. The methodology was efﬁcient not only at
distinguishing ginseng roots from different origin, but could also
discriminate material of the same origin, but of different age (Kang
et al., 2008). In a different study ﬁve Panax herbs were proﬁled
using ultra-performance liquid chromatography–quadrupole TOF
MS (UPLC–QTOFMS) and multivariate statistical analysis (Xie et al.,
2008). UPLC has the ability to generate many discrete peaks in a
short time, thus facilitating the simultaneous analysis of complex
samples with diverse chemical characteristics, while the high preci-
sion of the mass information generated with TOF MS  analysis allows
its application even in untargeted metabolite proﬁling. The method
proved reliable for the rapid analysis of a group of metabolites
present in the herbal extracts (Xie et al., 2008). Another method-
ology used in metabolomic proﬁling of CHM is hyphenated gas
chromatography–mass spectrometry. This methodology, coupled
with multivariate statistical analysis, has been used to discrimi-
nate and assess the quality of samples of three Curcuma species
from different ecotypes (genetically distinct geographic varieties,
populations or races within species adapted to speciﬁc environ-
mental conditions). Samples were analysed, and using principal
component analysis, partial least squares and discrimination anal-
ysis, characteristic components with an important inﬂuence on the
separation of the different groups were identiﬁed. The method-
ology thus not only discriminated efﬁciently among samples, but
the identiﬁcation of characteristic components provided new valid
chemical markers that have been proposed to be used for discrimi-
nation and quality control of Curcuma samples (Xiang et al., 2011).
The use of metabonomics has been welcomed by some as
the ultimate phenotyping. Using a systemic approach, it applies
a “top down” strategy to study the functions and perturbations of
a biological system, from the end products of the metabolic net-
work. This endows metabonomics with a holistic view, making
it closer to TCM thinking and particularly ﬁt to study pharmaco-
logical and toxicological effects of CHM (Lao et al., 2009; Wang
et al., 2005, 2011a,b,c; Zhang et al., 2010). Used with a holis-
tic approach, metabonomics has been also exploited to study
and characterise Chinese medicine syndromes in several experi-
mental models, recently reviewed (Wang et al., 2011a,b,c; Zhang
et al., 2010). Metabonomics involves global low molecular weight
metabolite proﬁling in complex biological ﬂuids or tissues to study
downstream homoeostatic perturbations in biochemical pathways.
One of the major beneﬁts of metabonomics is that urine or plasma
samples can be used for analysis, thus allowing large scale research.
Also metabolic proﬁling can, in the same experimental context, give
information of pathophysiological, pharmacodynamic, pharma-
cokinetic and diagnostic value. Nuclear magnetic resonance (NMR)
spectroscopy and mass spectrometry (MS), are the most used ana-
lytical techniques for metabonomic applications, following the
separation of metabolic components using gas chromatography
or, more often, UPLC. Combination of UPLC/MS is often used to
obtain the largest possible biochemical proﬁle. All metabolomic
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nd metabonomic studies result in complex multivariate datasets
hat need computer programmes for visualisation and chemomet-
ic as well as bioinformatic methods for interpretation (Zhang
t al., 2010). The therapeutic activity of a classical TCM formula,
iu Wei  Di Huang Wan  (LW), comprising a mixture of Radix
ehmanniae Preparata,  Fructus Corni Ofﬁcinalis,  Cortex Moutan
adicis (Paeonia Suffruticosa), Rhizoma Dioscoreae Oppositae,
clerotium Poriae Cocos and Rhizoma Alismatis Orientalis,  was
nvestigated in a rat model of shen yin deﬁciency, using a metabo-
omic approach. The experimentally induced condition of shen yin
eﬁciency was characterised by changes induced in the animals’
rine metabolic proﬁle, which were restored to their baseline val-
es following treatment with LW (Wang et al., 2010a,b).
A further study assessed the efﬁcacy of another TCM formula,
huanglong (a so-called ‘blooming tea’, usually comprising the
owers of Gomphrena globosa [red globe amaranth] and jasmine
often Jasminum sambac] in a base of tea [Camellia sinensis] leaves)
n myocardial infarction in rats. Urinary samples from treated and
ontrol rats were collected and analysed with UPLC/ESI-SYNAPTTM-
DMSTM. Potential urine biomarkers correlated well with serum
iochemistry and histopathology of myocardial infarction, and also
ith the beneﬁcial effect of the formula. The analysis of urinary
etabolic pathways also suggested that the Shuanglong effect is
inked with the regulation of myocardial energy metabolism (Liang
t al., 2011).
The therapeutic effect of Rhizoma Drynariae on an experimen-
al rat model of shen yang deﬁciency syndrome was investigated
y comparing urine proﬁles from diseased and treated rats. The
etabonomic patterns indicated that energy metabolism, amino
cid metabolism and gut microﬂora pathways were implicated in
he effect (Lu et al., 2011). Metabonomics has also been used to
roﬁle the metabolic ﬁngerprints of urine obtained from rats with
tress-induced chronic depression with and without treatment
ith Chaihu Shu Gan San (CSGS), a TCM formula, compris-
ng Bupleurum chinense, Citrus reticulata, Paeonia lactiﬂora, Citrus
urantium,  Cyperus rotundus, Ligusticum chuanxiong and Glycyrrhiza
ralensis, widely used for the treatment of depression. Metabolites
ith signiﬁcant changes were characterised as potential biomark-
rs involved in the pathogenesis of depression. Most of them
ere regulated by CSGS treatment suggesting that the effect of
SGS on depression might involve energy metabolism, tryptophan
etabolism, bone loss and liver detoxiﬁcation (Su et al., 2011).
A recent development has been the proposal of so-called
Fangjiomics’ as an approach involving in the design, production
nd pharmacological evaluation of herbal recipes (Wang et al.,
011a,b,c), acting through multiple targets, modes of action and
iological pathways. There are around 50 Fangji preparations. In
 similar to classical TCM use, every ingredient in a Fangji (for-
ula) is classiﬁed into 1 of 4 categories: in order of importance,
un (sovereign), Chen (minister), Zuo (assistant) or Shi (envoy).
enomics, proteomics and metabonomics are key approach of
angjiomics, since it is characterised by integration of information
rom many levels of study. Systems-based therapeutics could be
he next big challenge in the generation of new combination drugs,
nd their optimal use can be investigated in experimental models
ith omics.
. Good practice in the application of omics to TCM
esearch – report from GP-TCM discussion group on
unctional genomic techniquesGP-TCM (Good practice in traditional Chinese medicine research in
he post-genomic era) is an EU-China consortium on TCM research.
t was formed under the EU’s Seventh Framework Programme
ith the objective to revise the state of the art of TCM researchmacology 140 (2012) 535– 544 541
and propose guidelines for good practice in TCM research (Uzuner
et al., 2010).
Regarding the application of omics in TCM research, a ques-
tionnaire was  circulated in spring 2011 among a group of GP-TCM
researchers “D4.14 – Discussion group on use of functional genomic
techniques for in vitro CHM research” (the original document can
be consulted on http://www.gp-tcm.org/about/deliverables).  The
questionnaire addressed issues related to the use of omic tech-
niques in TCM research and most researchers agreed on several
pros and cons. The most relevant conclusions were:
• Quality control of the test material at all stages of preparation and
production and its standardisation still remain the main barrier
to meaningful research, but omic techniques can and increasingly
do contribute signiﬁcantly to this important aspect.
• Thanks to its wider view of biological systems and closer view of
simultaneous multiple effects exerted by phytocomplexes, sys-
tems biology can contribute to increased participation of CHM in
the scientiﬁc mainstream.
• Omic technologies are excellent at providing information on
whole collections of molecules. These can then either be studied
further using a reductionist approach to establish the properties
and function of each or to try to understand and validate the
relationship between them and their functions.
For these reasons, one single methodology is not consid-
ered sufﬁcient to investigate mechanisms of action of CHM. A
well-consolidated pipeline should be used comprising in silico eval-
uation, in vitro and in vivo validation through a combination of
classical biochemical signalling work, conventional molecular biol-
ogy, omics technology and bioinformatics.
5. Conclusions and future directions
Omic methodologies were developed in response to the need
for information-rich, coherent molecular biological strategies and
have been applied to different phases of CHM research start-
ing from standardisation and quality control of herbal formulae,
characterisation of target-mediated and downstream effects, the
identiﬁcation of molecular mechanisms to prediction of side effects
and interactions with other drugs. Thanks to their potential to
unveil the complex pharmacological networks induced by com-
plex herbal preparations, omic techniques can thus be considered
a powerful tool to address many open questions in CHM research.
Despite the many advantages of omic techniques, caution still
surrounds their application to CHM, and to pharmacognosy in
general, mainly because of the current limited experience. Never-
theless, there is a common and general recognition that a systems
biology approach is the best answer to study phytocomplexes. The
results obtained so far with the applications of omic technologies
have been promising but much more work needs to be undertaken
to examine their full potential in CHM and wider TCM research.
Indeed, it could be argued that the study of TCM is a perfect ﬁeld for
the demonstration of the beneﬁts of systems biology using all the
emerging technologies because of the recognition that a disease is
usually not a single target issue, but a complex perturbation involv-
ing multiple pathways, a recognition of the fact that TCM follow just
this principle (Wang et al., 2005). While all the omic techniques
are slowly but ﬁrmly pushing their way further in CHM research,
the youngest of them, metabonomics, seems to be rapidly gaining
ground with respect to the others. This is probably due to the sim-
plicity of the experimental design and to the better affordability of
the method, which allows direct and detailed analysis of large num-
bers of biological samples which, like urine, can be obtained very
easily. What is really attractive about metabonomics though is the
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ossibility of examining complete metabolic pathways and their
ntermingled interactions, in just one snapshot, taking a whole pic-
ure of the downstream outcomes of any biological perturbation.
his would appear as the ultimate systems biology phenotyping
nd is particularly ﬁt for studying TCM, with its holistic view of
iological effects. Accordingly, not only metabonomics is used to
tudy the action of Chinese formulae, but is being increasingly used
o successfully characterise TCM syndromes. Characterizing both
iagnostic Chinese medicine proﬁles and CHM pharmacological
ctivities with Western science-developed metabonomics, might
ctually lead to a faster and more efﬁcient way to bridge modern
estern medicine with Chinese medicine. Considering the rapid
volution of personalised medicine as a new model of systems biol-
gy approach to TCM (Naylor and Chen, 2010; Van der Greef et al.,
006), the time might have come to open new avenues towards
n integrative medical approach exploiting the knowledge of both
riental and Western medicine backgrounds.
. Suggestions for further guidelines
The consortium has identiﬁed at least two main issues which
eed to be addressed in the ﬁeld of omics in CHM studies using
xperimental models of disease:
6.1: There is an intrinsic problem of replicating the patterns
f human disease in animal or cellular models. Both types of
odel are rarely a close representation of the clinical scenario and
re not widely accepted as authentic, or standard – indeed some
nimal or disease models are not even clearly characterised or val-
dated. Therefore prior validation and standardisation of animal
odels where omics could be applied to the study of TCM is an
bsolute requirement, as has been the case in Western medicine
esearch.
6.2: Omics methods are extremely powerful but since they
pproach the basic components of the systems studied, they are
lso liable to variability. A particular source of variability however
hat has not been generally considered in most publications on
HM in experimental models of disease is the generalised use of
on-standardised research materials (in terms of the constituent
erbs and herbal preparations), which itself promotes variation.
his lack of rigour signiﬁcantly reduces the scientiﬁc value and
mpact of these studies. This implies that before using difﬁcult and
xpensive omic technologies, it is necessary to have a robust con-
rol of plant mixture preparation (batch to batch variability), asL
ic study in TCM research.
well as the experimental model: cell cultures and animal system
(organism variability as well as technical procedures). In addition,
pharmacokinetic (absorption, distribution, metabolism and excre-
tion) proﬁling of a given CHM will identify in vitro and in vivo
bioavailable drug-like components and reveal determining factors
for availability, dynamics and individual variations of ‘real’ active
components to target sites of action.
Without addressing these two  basic problems, omics research
in TCM may  fall foul of discipline, and descend to anarchy. Given
that omic technologies may  help elucidate the mechanism of action
of a given CHM treatment, we suggest that these studies have to
be applied on those CHM treatments the efﬁcacies of which have
been previously demonstrated. Since most relevant pieces of evi-
dence on efﬁcacy come from clinical trials, it is thus advisable to
start applying omic technologies to animal models of diseases for
which efﬁcacy has been proven in clinical trials. This would render
a number of TCMs relatively easy to deal with.
In this context, we  propose the scheme in Fig. 3 for starting suc-
cessfully to apply omics in TCM research. Additionally, we propose
the following workﬂow for applying omics in experimental in vitro
and in vivo models:
(1) To use a TCM proven to be efﬁcacious in an appropriate exper-
imental model by gold-standard measurement methods.
(2) To assess variability in TCM composition and select a uniform,
appropriately deﬁned batch.
(3) To assess variability in the organism population (cell cultures
or animals) by carrying out pre-testing omic studies, including
metabolic proﬁles.
(4) To assess the known levels of analytical variation in relation
to the changes observed (whether at the transcript, protein or
metabolism levels).
(5) To deﬁne precisely the experimental groups as well as their
size in terms of number of cell types or animals to make pre-
cise statistical analysis. It will also be desirable to choose a
homogeneous experimental population as far as possible.
(6) To check that the effects observed in cell cultures or animal
after TCM use, especially if chronic administration is necessary,
are due to the treatment and not to some other variable (e.g.,
cell passage, proliferation, aging or body weight changes). As
much data must be collected as possible in case any of the above
differences need to be explained.
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7) To perform the appropriate omic technique and analysis
accordingly to the available guidelines on omics standardisa-
tion in the literature, such as MIAME  (minimum information
about a microarray experiment) for transcriptomics (Brazma
et al., 2001), MIAPE (minimum information about a pro-
teomics experiment) for proteomics (Taylor et al., 2007), and
MSI  (the metabolic standards initiative; website: http://msi-
workgroups.sourceforge.net)  for metabolomics.
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